In this sense, several studies have focused on mutations in the DHPS gene, which encodes the enzyme dihydropteroate synthase, which has been described for its potential association with the development of resistance to sulfonamides and is currently considered the drug of choice for the prophylaxis and treatment of PCP [66]. This evidence concerns the gene DHPS and pneumocystosis.